Cheezheng Tibetan Medicine Releases 2026 Interim Report with Net Profit of 371 Million Yuan

Earnings
โดย Jiemian·CN·Read original
Summary · why it matters

Cheezheng Tibetan Medicine released its 2026 interim report, with net profit attributable to the parent company of 371 million yuan. The company's total operating revenue was 978 million yuan, down 16.77 percent from the same period last year. Net cash inflow from operating activities was 239 million yuan, down 51.25 percent year on year. The company's latest gross margin was 82.08 percent, latest return on equity was 7.28 percent, and diluted earnings per share was 0.66 yuan.

Impact on stocks 1

Others▼ · 1 stocks
© 2026 MarketDXNews